Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL SUSTAINED RELEASE OCULAR DRUG DELIVERY SYSTEMS INDUSTRY
2.1 Summary about Sustained Release Ocular Drug Delivery Systems Industry
2.2 Sustained Release Ocular Drug Delivery Systems Market Trends
2.2.1 Sustained Release Ocular Drug Delivery Systems Production & Consumption Trends
2.2.2 Sustained Release Ocular Drug Delivery Systems Demand Structure Trends
2.3 Sustained Release Ocular Drug Delivery Systems Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Liposome
4.2.2 Microcapsules/Nanocapsules
4.2.3 Microspheres/Nanosptheres
4.2.4 Implants
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Cataract
4.3.2 Glaucoma
4.3.3 Corneal Transplantation
4.3.4 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Liposome
5.2.2 Microcapsules/Nanocapsules
5.2.3 Microspheres/Nanosptheres
5.2.4 Implants
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Cataract
5.3.2 Glaucoma
5.3.3 Corneal Transplantation
5.3.4 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Liposome
6.2.2 Microcapsules/Nanocapsules
6.2.3 Microspheres/Nanosptheres
6.2.4 Implants
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Cataract
6.3.2 Glaucoma
6.3.3 Corneal Transplantation
6.3.4 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Liposome
7.2.2 Microcapsules/Nanocapsules
7.2.3 Microspheres/Nanosptheres
7.2.4 Implants
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Cataract
7.3.2 Glaucoma
7.3.3 Corneal Transplantation
7.3.4 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Liposome
8.2.2 Microcapsules/Nanocapsules
8.2.3 Microspheres/Nanosptheres
8.2.4 Implants
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Cataract
8.3.2 Glaucoma
8.3.3 Corneal Transplantation
8.3.4 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Liposome
9.2.2 Microcapsules/Nanocapsules
9.2.3 Microspheres/Nanosptheres
9.2.4 Implants
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Cataract
9.3.2 Glaucoma
9.3.3 Corneal Transplantation
9.3.4 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 pSivida
10.1.2 Allergan
10.1.3 Icon Bioscience
10.1.4 Ocular Therapeutix
10.1.5 Neurotech Pharmaceuticals
10.1.6 Santen Pharmaceutical
10.1.7 Aciont Inc.
10.1.8 Envisia Therapeutics
10.1.9 GrayBug
10.1.10 Innocore Pharmaceuticals
10.1.11 OHR Pharmaceuticals
10.1.12 PolyActiva
10.1.13 TheraKine
10.2 Sustained Release Ocular Drug Delivery Systems Sales Date of Major Players (2017-2020e)
10.2.1 pSivida
10.2.2 Allergan
10.2.3 Icon Bioscience
10.2.4 Ocular Therapeutix
10.2.5 Neurotech Pharmaceuticals
10.2.6 Santen Pharmaceutical
10.2.7 Aciont Inc.
10.2.8 Envisia Therapeutics
10.2.9 GrayBug
10.2.10 Innocore Pharmaceuticals
10.2.11 OHR Pharmaceuticals
10.2.12 PolyActiva
10.2.13 TheraKine
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.